Persistent URL of this record https://hdl.handle.net/1887/3274093
In Collections
This item can be found in the following collections:
Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"
- All authors
- Groenland, S.L.; Geel, D.R.; Beijnen, J.H.; Smit, E.F.; Huitema, A.D.R.; Steeghs, N.
- Date
- 2021-08-13